Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity
Source: SeekingAlpha
2026-05-08 10:58:39 ET
Investment Overview
Iovance Biotherapeutics, Inc. ( IOVA ), the San Carlos, California-headquartered Pharma company that markets and sells the tumor-infiltrating lymphocyte ("TIL") therapy Amtagvi (lifileucel) for patients with advanced melanoma, announced its Q1 earnings yesterday, 7th May, prompting a selloff of stock, which slipped to a a value of $3.55, down >13% for the day. Iovance's market cap pre-market today stood at $1.59bn....
Read the full article on Seeking Alpha
For further details see:
Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
28.78% G/L:
$5.19 Last:
9,599,164 Volume:
$3.99 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
